Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Number of employees : 262 people.
Sales per Business
20192020Delta
DNA Immunotherapies and Vaccines4.11100%7.41100% +80.24%
USD in Million
Sales per region
20192020Delta
United States4.11100%7.41100% +80.24%
USD in Million
Managers
Name Title Age Since
J. Joseph Kim, Dr. President, Chief Executive Officer & Director 51 2009
Peter D. Kies Chief Financial Officer 56 2002
Laurent M. Humeau, Dr. Chief Scientific Officer 53 2019
Kate E. Broderick, Dr. Senior Vice President-Research & Development - 2007
Mammen P. Mammen, Dr. Senior Vice President-Clinical Development 56 2020
Stephen Kemmerrer Senior Vice President-Engineering Development - 2007
Jacqueline E. Shea, Dr. Chief Operating Officer & Executive Vice President 54 2019
Simon X. Benito Chairman 75 2019
Wendy L. Yarno Independent Director 65 2017
Lota S. Zoth Independent Director 60 2019
Members of the board
Name Title Age Since
Simon X. Benito Chairman 75 2019
J. Joseph Kim, Dr. President, Chief Executive Officer & Director 51 2009
David B. Weiner, Dr. Director 64 2016
Wendy L. Yarno Independent Director 65 2017
Lota S. Zoth Independent Director 60 2019
Ann Calby Miller, Dr. Independent Director 62 2019
Jay P. Shepard Independent Director 62 2020
Roger Dansey Director 63 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 210,356,896 206,874,425 98.3% 0 0.0% 98.3%
Stock B 0 1,091 0 0.0% 1,082 99.2%
Stock C 0 9 0 0.0% 0 0.0%
Shareholders
NameEquities%
The Vanguard Group, Inc. 10,580,257 5.03%
SSgA Funds Management, Inc. 8,907,158 4.23%
BlackRock Fund Advisors 5,926,355 2.82%
Nikko Asset Management Co., Ltd. 5,156,350 2.45%
Avidity Partners Management LP 4,004,391 1.90%
Geode Capital Management LLC 3,623,488 1.72%
Wasatch Advisors, Inc. 3,576,706 1.70%
JPMorgan Asset Management (UK) Ltd. 3,298,716 1.57%
Coatue Management LLC 3,126,923 1.49%
Venrock Associates 2,900,000 1.38%
Company contact information
Inovio Pharmaceuticals, Inc.
660 West Germantown Pike
Suite 110
Plymouth Meeting, PA 19462-1111

Phone : +1.267.440.4200
Fax : +1.267.440.4242
Web : http://www.inovio.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Inovio Pharmaceuticals, Inc.